These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 6347792)

  • 1. [Hepatitis caused by various derivatives of erythromycin].
    Funck-Brentano C; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cholestatic hepatitis caused by erythromycin estolate].
    García Monzón C; Noguerado A; Hidalgo S; Escudero V
    Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB; Reis TC; Berland JE
    Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erythromycin-induced hepatitis].
    Perrier M; Portier G; de Calan L; Favre JP; Ozoux JP; Rivallain B; Brizon J
    Cah Anesthesiol; 1987; 35(3):237. PubMed ID: 3621021
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
    Gafter U; Mandel EM; Weiss S; Djaldetti M
    N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477
    [No Abstract]   [Full Text] [Related]  

  • 6. Selection of an oral erythromycin product.
    Fraser DG
    Am J Hosp Pharm; 1980 Sep; 37(9):1199-205. PubMed ID: 6998290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA begins proceedings to remove erythromycin estolate from market.
    FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836
    [No Abstract]   [Full Text] [Related]  

  • 8. [Acute hepatitis caused by erythromycin esters (propionate and ethylsuccinate)].
    Paliard P; Stremsdoerfer N; Moindrot H
    Gastroenterol Clin Biol; 1983 Jan; 7(1):100-1. PubMed ID: 6601598
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hepatitis due to erythromycin ethylsuccinate].
    Funck-Brentano C; Danan G; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1982 Dec; 6(12):1044-5. PubMed ID: 6984402
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk-benefit equation for erythromycin estolate.
    LeBel M
    Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete biliary obstruction due to erythromycin estolate administration in an infant.
    Krowchuk D; Seashore JH
    Pediatrics; 1979 Dec; 64(6):956-8. PubMed ID: 514726
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythromycin propionate and estolate.
    Farre M
    Lancet; 1988 Jul; 2(8601):45. PubMed ID: 2898648
    [No Abstract]   [Full Text] [Related]  

  • 13. Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases.
    Diehl AM; Latham P; Boitnott JK; Mann J; Maddrey WC
    Am J Med; 1984 May; 76(5):931-4. PubMed ID: 6609640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ilosone update.
    Culp ER
    Am Fam Physician; 1980 Apr; 21(4):23. PubMed ID: 7377065
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cholestasis hepatitis caused by erythromycin propionate].
    Ortuño JA; Olaso V; Berenguer J
    Med Clin (Barc); 1984 May; 82(20):912. PubMed ID: 6748800
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cholestatic hepatitis caused by erythromycin propionate].
    de Escalante B; Sampedro JA; Zabala S; Gracia P
    An Med Interna; 1990 Dec; 7(12):656. PubMed ID: 2135589
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective study on the incidence of liver function abnormalities in children receiving erythromycin estolate, erythromycin ethylsuccinate or penicillin V for treatment of pneumonia.
    Ginsburg CM
    Pediatr Infect Dis; 1986; 5(1):151-3. PubMed ID: 3080735
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatotoxicity of erythromycin derivatives.
    Pessayre D; Benhamou JP
    Br Med J; 1979 May; 1(6174):1357. PubMed ID: 445081
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythromycin ethylsuccinate hepatotoxicity.
    Sullivan D; Csuka ME; Blanchard B
    JAMA; 1980 Mar; 243(10):1074. PubMed ID: 6965509
    [No Abstract]   [Full Text] [Related]  

  • 20. Cholestasis and liver cell damage due to hypersensitivity to erythromycin stearate--recurrence following therapy with erythromycin succinate.
    Horn S; Aglas F; Horina JH
    Wien Klin Wochenschr; 1999 Jan; 111(2):76-7. PubMed ID: 10081126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.